Clarivate partners with KYBORA to expand biopharma transaction advisory services

• Clarivate partnered with investment bank KYBORA to provide end-to-end transaction advisory services for biopharma companies.
• Offering targets strategic transactions including M&A, licensing, and capital raising, combining life sciences intelligence with deal execution support.
• Partnership aims to help clients assess asset value, sharpen investment narratives, engage partners earlier, and improve transaction outcomes.
• KYBORA has completed nearly 100 biopharma M&A, licensing, and fundraising transactions worldwide.
• Coverage spans North America, Europe, Latin America, and Asia Pacific to reach key biopharma markets and investor communities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.